Ritonavir-boosted nirmatrelvir
Revision as of 20:26, 18 January 2022 by Rossdonaldson1 (talk | contribs)
Administration
- Type:
- Dosage Forms: Oral
- Routes of Administration:
- Common Trade Names: Paxlovid
Adult Dosing
COVID
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- Treatment of high risk patients with mild-to-moderate disease
- Initiate within 5 days of symptom onset
Pediatric Dosing
COVID
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- 12 years of age and older weighing at least 40 kilograms
- Treatment of high risk patients with mild-to-moderate disease
- Initiate within 5 days of symptom onset
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Renally dosed: if eGFR 30-60, then 150 mg/100 mg dosing
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Many drug interactions
- E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.